Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
Liyan Guo, Sheng Lin, Zimin Chen, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 46
Nucleoside‐Based Drug Target with General Antimicrobial Screening and Specific Computational Studies against SARS‐CoV‐2 Main Protease
Sarkar M. A. Kawsar, Md. Ahad Hossain, Supriyo Saha, et al.
ChemistrySelect (2024) Vol. 9, Iss. 15
Closed Access | Times Cited: 25
Engineering tobacco for efficient astaxanthin production using a linker-free monocistronic dual-protein expression system and interspecific hybridization method
Ning Fang, Zaifeng Du, Xiaofeng Liu, et al.
Plant Physiology and Biochemistry (2025) Vol. 221, pp. 109607-109607
Closed Access | Times Cited: 1
The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target
Teresa Santos-Mendoza
Viruses (2023) Vol. 15, Iss. 4, pp. 1000-1000
Open Access | Times Cited: 18
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 7
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Fragment-based screening targeting an open form of the SARS-CoV-2 main protease binding pocket
Chia‐Ying Huang, A. Metz, Roland Lange, et al.
Acta Crystallographica Section D Structural Biology (2024) Vol. 80, Iss. 2, pp. 123-136
Open Access | Times Cited: 6
Synthesis, molecular docking analysis, molecular dynamic simulation, ADMET, DFT, and drug likeness studies: Novel Indeno[1,2-b]pyrrol-4(1H)-one as SARS-CoV-2 main protease inhibitors
Davood Gheidari, Morteza Mehrdad, Mohammad Bayat
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299301-e0299301
Open Access | Times Cited: 6
Molecules for COVID-19 treatment
Zhigang Zeng, Changzhou Liao, Lei Yu
Chinese Chemical Letters (2023) Vol. 35, Iss. 7, pp. 109349-109349
Closed Access | Times Cited: 14
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
Vivek P. Chavda, Divya Teli, Pankti C. Balar, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2332-2332
Open Access | Times Cited: 13
Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
Xiang Zhao, Yuan Cheng, Meng Zhang, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 6053-6060
Open Access | Times Cited: 13
A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
Yang Yang, Junfang Zhang, Shengnan Zhang, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 13
Ubiquitin Ligase Parkin Regulates the Stability of SARS-CoV-2 Main Protease and Suppresses Viral Replication
Li Zhou, Ruochuan Liu, Heather Pathak, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 3, pp. 879-889
Open Access | Times Cited: 5
Procyanidins inhibit alphacoronavirus infection by reducing interferon antagonism
Yi Liu, Xue Wang, Xuefei Wang, et al.
Phytomedicine (2025) Vol. 140, pp. 156549-156549
Closed Access
Targeting Two-Tetrad RNA G-Quadruplex in the SARS-CoV-2 RNA Genome Using Tetraphenylethene Derivatives for Antiviral Therapy
P. C. Sen Gupta, Rushikesh M. Khadake, Oinam Ningthemmani Singh, et al.
ACS Infectious Diseases (2025)
Closed Access
T and B cell responses in different immunization scenarios for COVID-19: a narrative review
Eva Piano Mortari, Pier Francesco Ferrucci, Irini Zografaki, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
An Intranasal Nanomedicine Functions as Both Potent Broad‐spectrum Viral Inhibitor and Quasi‐Vaccine
Jingran Chen, Ying Li, Li Xiao, et al.
Advanced Functional Materials (2025)
Closed Access
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics
Fangzhou Li, Qianqian Huang, Ziran Zhou, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 11
Bruton's tyrosine kinase inhibition for the treatment of allergic disorders
Erica V. Lin, Ragha Suresh, Melanie C. Dispenza
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 1, pp. 33-42
Open Access | Times Cited: 4
Magnolol against enterovirus 71 by targeting Nrf2-SLC7A11-GSH pathway
Dingran Zhao, Xueyang Guo, Binbin Lin, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116866-116866
Open Access | Times Cited: 4
An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
Mehdi Valipour, Hamid Irannejad, Hossein Keyvani
ACS Pharmacology & Translational Science (2023) Vol. 6, Iss. 9, pp. 1248-1265
Open Access | Times Cited: 9
Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies
Chunye Zhang, Yuxiang Sui, Shuai Liu, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1479-1479
Open Access | Times Cited: 7
Microfluidic-assisted single-cell RNA sequencing facilitates the development of neutralizing monoclonal antibodies against SARS-CoV-2
Ziwei Wang, Amelia Siqi Huang, Lingfang Tang, et al.
Lab on a Chip (2024) Vol. 24, Iss. 4, pp. 642-657
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top